TRICE - Phase I/II Study of The Adjuctive Use Of Nilotinib In Patients Undergoing Reduced Intensity Allogeneic Transplantation For Imatinib Resistant Or Intolerant Chronic Myeloid Leukaemia

  • Craddock, Charles (Principal Investigator)

Project Details

Short titleTRICE - Phase I/II Study of The Adjuctive Use Of Nilotinib In Patients Undergoing Reduced Intensity Allogeneic Transplantation For Imatinib Resistant Or Intolerant Chronic Myeloid Leukaemia
StatusFinished
Effective start/end date14/11/08 → 31/08/15

Funding

  • NOVARTIS PHARMACEUTICALS UK LTD